About Avedro
Avedro is a company based in Waltham (United States) founded in 2007 was acquired by Glaukos in August 2019. Avedro has raised $210.76 million across 11 funding rounds from investors including Glaukos, Flagship Pioneering and Orbimed. The company has 113 employees as of December 31, 2022. Avedro operates in a competitive market with competitors including CorneaGen, EyeGate, Cellusion, EyeYon and CorNeat Vision, among others.
- Headquarter Waltham, United States
- Employees 113 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avedro, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Avedro
Avedro has successfully raised a total of $210.76M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $25 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Avedro
Avedro has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Glaukos, Flagship Pioneering and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked | |
|
Investments are focused on tech and life sciences startups.
|
Locked | Locked | Locked |
Investor details for Avedro
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avedro
Investment portfolio details for Avedro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avedro
Detailed financials for Avedro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avedro Comparisons
Peer comparison for Avedro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avedro
Avedro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, EyeGate, Cellusion, EyeYon and CorNeat Vision, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for corneal transplants are developed by CorneaGen.
|
|
| Locked | Locked | Locked |
Therapeutics and drug delivery systems for eye diseases are developed.
|
|
| Locked | Locked | Locked |
iPS cell-based technology for corneal endothelium regeneration is developed.
|
|
| Locked | Locked | Locked |
Ophthalmic devices for corneal edema treatment are developed.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
Detailed competitors of Avedro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avedro
Complete news archive for Avedro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avedro
Avedro was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Avedro is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Avedro is a funded company, having raised a total of $210.76M across 11 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Avedro is 113.
Developer of corneal collagen cross-linking technology. Its products, the VibeX and KXL System for performing Lasik Xtra and accelerated cross-linking have been commercialized outside the US. It also received approval from the China FDA for its KXL system in Nov 2015.
Avedro has 14 investors. Key investors include Glaukos, Flagship Pioneering, Orbimed, Abingworth, and Lilly Asia Ventures.